Tech Company Financing Transactions
Nuevocor Funding Round
Nuevocor closed a $45 million Series B funding round on 5/6/2025. Investors included Angelini Ventures, Kurma Partners and Boehringer Ingelheim Venture Fund.
Transaction Overview
Company Name
Announced On
5/6/2025
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support the Phase 1/2 clinical trial of lead candidate, NVC-001, in patients with LMNA-related dilated cardiomyopathy (LMNA DCM).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1 Biopolis Drive, Amnios 05-01
Singapore, 138622
Singapore
Singapore, 138622
Singapore
Phone
Undisclosed
Website
Email Address
Overview
Nuevocor, with offices in USA and Singapore, is developing genetic medicines for untreatable genetic cardiomyopathies by leveraging insights from our PrOSIA mechanobiology platform.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Andreas Wallnoefer
Chief Executive Officer
Yann Tan
Chief Medical Officer
John Lee
VP - Bus. Development
Christian Beck
VP - Operations
Cheryl Lee
VP - Operations
Susan Maloney
VP - Operations
Robert Piperno
Browse more venture capital transactions:
Prev: 5/6/2025: Posha venture capital transaction
Next: 5/6/2025: Floral Energy venture capital transaction
Share this article
About Database of VC Transactions
We report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs